Method of evaluating physical dependence liability to sedative-hypnotic agents in small animals
نویسندگان
چکیده
منابع مشابه
155 - Sedative-Hypnotic Agents
Barbiturates were formerly the primary sedative-hypnotic agents used clinically. Currently, they are most often encountered as anticonvulsants, induction agents for anesthesia, and agents used for procedural sedation. Because the barbiturates have largely been replaced clinically by benzodiazepines due to safety concerns, their prevalence in overdoses has drastically decreased when compared wit...
متن کاملTreatment of insomnia in older adults: re-evaluating the benefits and risks of sedative hypnotic agents.
Insomnia and sleep complaints are common among older adults. Although once considered safer than benzodiazepine drugs, recent data on non-benzodiazepine drugs, such as zolpidem (Ambien(®)), have revealed similar negative effects. This issue, as well as others, has been included in the recent updated 2012 American Geriatrics Society Beers Criteria. This article describes the risks and benefits a...
متن کاملSedative-Hypnotic and Anxiolytic Drugs
The primary use of sedative–hypnotic and anxiolytic drugs is to encourage calmness (anxiolytics or sedatives) or to produce sleep (sedative–hypnotics). All people are subject to states of emotional tension and uneasiness. For otherwise healthy individuals, these occasions are usually sufficiently mild and short that pharmacological intervention is unnecessary. However, at times the symptoms of ...
متن کاملContribution of sedative-hypnotic agents to delirium via modulation of the sleep pathway
PURPOSE To review the mechanisms of sedative-hypnotic action with respect to the risk of delirium imparted by drugs that act on γ-amino-butyric-acid type A receptors or α(2) adrenoceptors. SOURCE MEDLINE was searched for relevant articles. PRINCIPAL FINDINGS Development of the acute confusional state of delirium is associated with longer intensive care unit (ICU) and hospital lengths of sta...
متن کاملRamelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
CONTEXT Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment. Most approved insomnia medications have potential for abuse and cause motor and cognitive impairment. OBJECTIVE To evaluate the potential for abuse, subjective effects, and motor and cognitive-impairing effects of ramelteon compared with triazolam, a classic benzodiazepine s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1978
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)67102-7